Search Bar & Filters
Found 23 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
This trial investigates the effects of different durations of fasting after esophageal variceal ligation therapy in patients with cirrhosis and portal hypertension. Researchers aim to compare early postoperative oral intake with a 6-hour fasting period against delayed oral intake with fasting periods of 24 or 48 hours. The study evaluates the safety and effectiveness of these approaches in reducing early postoperative rebleeding. Participants are randomly assigned to one of three groups with varying fasting durations after ligation surgery 6 hours, 24 hours, or 48 hours. The 6-hour fasting group begins with a liquid diet during the first day after surgery, progressing to semi-liquid or soft diets by days 4-7, and regular diets starting day 8. The groups fasting 24 or 48 hours receive intravenous fluids during fasting, followed by gradual diet progression similar to the 6-hour group. This study is conducted across multiple centers and uses a quadruple-blind design. During the study, participants will be monitored for early rebleeding events over 6 weeks, with additional assessments of hospital stay length, nutritional status, and non-bleeding adverse events over 4 weeks. Researchers will track diet tolerance and complications through scheduled visits and evaluations. The study runs from June 2026 to June 2027, with careful safety and outcome monitoring to understand the impact of fasting duration on recovery after variceal ligation.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating a facial image-based artificial intelligence AI algorithm designed to screen for coronary artery disease CAD in high-risk community populations, including those with diabetes, hypertension, or aged over 65. The study aims to verify if the AI can accurately identify high-risk and low-risk groups by comparing the actual CAD prevalence, and to compare the AI screening detection rate with natural detection rates in a real-world cohort. Participants are divided into two groups. One group undergoes AI-based facial image screening followed by Coronary Computed Tomography Angiography CCTA to confirm CAD diagnosis. The other group represents a real-world setting without the AI screening and is observed to track natural CAD detection and major adverse cardiovascular events MACE over a six-month follow-up period. During the study, all participants receive monitoring for six months to assess CAD presence and cardiovascular outcomes, including heart attacks and revascularization procedures. Researchers will measure differences in CAD prevalence between AI-identified risk groups, detection rates of CAD, and the incidence of cardiovascular events and deaths. This follow-up period helps evaluate the AI screenings performance compared to usual detection methods.
Actively Recruiting
Researchers are studying the use of albumin combined with endovascular treatment in patients who have an acute ischemic stroke in the anterior circulation. This trial is a prospective, multicenter, open-label, randomized controlled study aiming to determine the safety and effectiveness of adding albumin to the standard endovascular therapy for this condition. Patients will be selected based on specific criteria including stroke severity and imaging findings. Participants will be randomly assigned to one of two groups one receiving albumin along with endovascular treatment, and the other receiving only the recommended endovascular treatment. Albumin is given as a 25% human albumin intravenous infusion at a dose of 0.5gkg maximum 37.5g once initially and then daily for the next three days. Both groups will also receive acute stroke care and secondary prevention therapies according to current guidelines. During the study, participants will undergo initial imaging tests such as CT or MRI scans to confirm stroke location and exclude hemorrhage, along with laboratory tests and stroke severity assessments including the NIH Stroke Scale and modified Rankin Scale. Vital signs will be monitored, and patients will be followed for 90 days after randomization via telephone to evaluate their recovery and quality of life. The primary outcome is the proportion of patients achieving good functional status or returning to their baseline by 90 days.
Actively Recruiting
Primary aldosteronism PA is a common cause of secondary hypertension, and its diagnosis and treatment pose significant challenges. This research investigates adrenal venous sampling AVS, which is considered the best method to distinguish between different types of PA. The study aims to address clinical, technical, and methodological questions about AVS and to understand how AVS-guided management influences long-term health and biochemical results to improve patient care. Participants with PA will undergo adrenal venous sampling through either the antecubital or femoral vein to identify whether aldosterone overproduction is unilateral or bilateral. This observational study evaluates the AVS procedure itself and its clinical outcomes, refining protocols and standardizing practices to optimize treatment decisions and patient prognosis. Throughout the study, researchers will monitor major cardiovascular events one year after AVS. They will also assess procedure success rates, complications, medication changes, blood pressure, heart and kidney function, and clinical outcomes over multiple years. The follow-up includes assessments at 1, 3, 6, 12, 18 months, and up to 10 years, enabling comprehensive evaluation of long-term effects and safety.
Actively Recruiting
Healthy Volunteer
The China Healthy Aging and Dementia HEAD study is a large, community-based research effort in China aiming to enroll over 20,000 participants from various regions including eastern, northern, southern, western, and central areas. It focuses on studying Alzheimers disease and related dementias ADRD by collecting extensive clinical, neuroimaging, biospecimen, and multi-omics data. The goal is to improve early prediction and diagnosis of ADRD and support future intervention research in the Chinese population. Participants undergo a range of assessments at the start, including questionnaires, neuropsychological tests, physical measurements, and biospecimen collection. Some also receive electrophysiologic tests and brain imaging like MRI and PET scans. Biospecimens collected include blood, urine, stool, mucosal secretions, and cerebrospinal fluid when feasible. The study will follow participants approximately annually for up to 50 years, with repeated tests and biospecimen collection as possible. During participation, individuals complete cognitive and emotional evaluations, physical exams, and provide samples for laboratory and multi-omics analyses. Researchers measure cognitive decline and dementia progression using tools such as the Mini-Mental State Examination MMSE, Montreal Cognitive Assessment MoCA, and Clinical Dementia Rating Scale. They also monitor biomarkers and brain changes via imaging and laboratory tests. The study aims to understand risk factors, develop predictive models, and validate diagnostic criteria for ADRD over long-term follow-up.
Actively Recruiting
Researchers are evaluating the long-term effectiveness and safety of drug-coated balloon DCB strategies, including DCB alone or combined with drug-eluting stents DES, compared to DES-only treatment in patients with chronic total occlusion CTO of coronary arteries after successful reopening. This multicenter randomized controlled trial aims to fill the gap in direct comparative data between DCB and DES treatments for CTO, with the goal of optimizing treatment strategies, reducing stent use, lowering complication risks, and improving patient outcomes. Participants will be randomly assigned to either the DCB group, which involves balloon angioplasty with drug coating and possible provisional DES implantation if needed hybrid strategy, or the DES-only group receiving standard drug-eluting stent placement. Both groups receive standard medical therapy including at least 12 months of dual antiplatelet therapy DAPT. The study includes a 9-month primary endpoint assessment and a 36-month follow-up period to monitor long-term outcomes. During the study, patients will undergo angiographic evaluation for late lumen loss at 9 months, assessed by an independent laboratory using quantitative coronary angiography. Clinical events such as target lesion failure, cardiac death, myocardial infarction, and repeat revascularization will be monitored up to 36 months. Patient-reported outcomes like angina status and quality of life, as well as intravascular imaging and safety parameters, will also be collected. Overall participation spans over three years with regular follow-up visits to assess treatment effects and safety.
Actively Recruiting
Stroke is one of the leading causes of death worldwide, with ischemic stroke being the most common type. Researchers are evaluating whether early administration of oral aspirin after intravenous thrombolysis improves functional outcomes for patients with acute ischemic stroke. The study aims to determine if starting aspirin treatment within 3 hours of thrombolysis can prevent neurological deterioration without increasing bleeding risks. Participants are randomly assigned to one of two groups the interventional group receives 300 mg of oral aspirin shortly after starting intravenous thrombolysis, while the control group receives a placebo. Both groups receive the best standard medical care according to current guidelines. Aspirin tablets may be chewed or given via a nasogastric tube if swallowing is difficult. The treatment is administered within 3 hours of initiating thrombolysis. During the study, participants are monitored for neurological improvements and potential complications using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days after stroke. Researchers will assess functional outcomes, neurological changes, and safety measures, including the risk of intracranial hemorrhage. The total follow-up period extends to 90 days post-stroke.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of combining an interleukin-6 inhibitor called tocilizumab with endovascular therapy in adults who have experienced an acute posterior circulation large-vessel occlusion stroke. This phase III clinical trial aims to see if adding tocilizumab can improve recovery outcomes for these patients. The trial is randomized, double-blind, and placebo-controlled, ensuring a rigorous comparison between treatments. Participants will receive either endovascular treatment combined with a single intravenous infusion of 240 mg tocilizumab or endovascular treatment combined with a placebo infusion. The infusion will be given immediately after randomization within 30 minutes and will take more than one hour to complete. This study involves two groups running in parallel to compare the effects of tocilizumab against placebo. During the study, participants will be assessed on their recovery using the modified Rankin Scale at 90 days as the main measure. Additional assessments include neurological improvement shortly after treatment, stroke severity scores at 7 days, and quality of life evaluations up to one year. Safety and functional outcomes will be closely monitored through various scales and indexes, with the total follow-up lasting up to one year after treatment.
1-10 of 23
1